Login to Your Account

HAE trial's second analysis injects Biocryst confidence over Shire bid

By Randy Osborne
Staff Writer

Thursday, May 25, 2017

After the success by Shire plc with its injectable kallikrein inhibitor, lanadelumab, for HAE, investor hopes swelled for Biocryst Pharmaceuticals Inc.'s oral BCX-7353.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription